Molecular bases of vaccine-prevention of plague

Dentovskaya, Svetlana V.; Копылов, П. Х.; Ivanov, Sergey A.; Ageev, S. A.; Anisimov, Andrey P.

doi:10.3103/s089141681303004x

Cited by 17 publications

(24 citation statements)

References 116 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This vaccine or similar live attenuated bacteria with designations including EV76, EV NIIEG and Tjiwide were administered to millions of people in Madagascar, Indonesia, Vietnam, and the Soviet Union [24, 25]. Vaccinum pestosum vivum siccum on the base of the strain EV line NIIEG is still used and commercially available in Russia (http://www.epidemiolog.ru/catalog_vac/?SECTION_ID=&ELEMENT_ID=476) and Kazakhstan (http://pharmprice.kz/annotations/vakcina-chumnaya-zhivaya-suhaya/) [26]. By the end of the 20th century, these vaccines were rarely used outside of Russia due to their strong adverse reactions.…”

Section: Brief History Of Plague Vaccinesmentioning

confidence: 99%

“…In 1936, a subculture of the EV76 vaccine strain was established at the NIIEG (designation based on the Russian abbreviation of the Scientific-Research Institute for Epidemiology and Hygiene, Kirov, Russian Federation) in the former USSR [112]. This strain was employed for the development of the live vaccine designated as “Vaccinum pestosum vivum siccum ”, which is manufactured in the former USSR from 1940 [26, 113]. The EV NIIEG strain has been used as a live plague vaccine for the protection of plague researchers and people living in territories endemic for plague in the countries of the former USSR and some Asian countries and is still in use today [113, 114].…”

Section: Live Attenuated Yersinia Vaccinesmentioning

confidence: 99%

“…route, such vaccines also offer the advantage of being easier and safer to administer than needle-based delivery [163]. Therefore, live attenuated vaccines have advantages over subunit vaccines as they are typically taken orally, still inducing strong mucosal and durable immunity [26, 162, 164]. In addition, they are often less expensive to manufacture than subunit vaccines.…”

Section: Live Vectored Plague Vaccinesmentioning

confidence: 99%

See 2 more Smart Citations

Plague Vaccines: Status and Future

Sun

2016

Advances in Experimental Medicine and Biology

View full text Add to dashboard Cite

Three major plague pandemics caused by the gram-negative bacterium Yersinia pestis have killed nearly 200 million people in human history. Due to its extreme virulence and the ease of its transmission, Y. pestis has been used purposefully for biowarfare in the past. Currently, plague epidemics are still breaking out sporadically in most of parts of the world, including the United States. Approximately 2000 cases of plague are reported each year to the World Health Organization. However, the potential use of the bacteria in modern times as an agent of bioterrorism and the emergence of a Y. pestis strain resistant to eight antibiotics bring out severe public health concerns. Therefore, prophylactic vaccination against this disease holds the brightest prospect for its long-term prevention. Here, we summarize the progress of the current vaccine development for counteracting plague.

show abstract

Section: Brief History Of Plague Vaccinesmentioning

confidence: 99%

Section: Live Attenuated Yersinia Vaccinesmentioning

confidence: 99%

Section: Live Vectored Plague Vaccinesmentioning

confidence: 99%

See 1 more Smart Citation

Plague Vaccines: Status and Future

Sun

2016

Advances in Experimental Medicine and Biology

View full text Add to dashboard Cite

show abstract

“…On the other hand, it is one of immunodominant antigens responsible for protective immunity against plague [8, 60, 61]. Accordingly, it has been used as the major molecular target for immunodiagnostics, and as a principal component of the vaccines [8, 60–63].…”

Section: Discussionmentioning

confidence: 99%

Yersinia pestis Caf1 Protein: Effect of Sequence Polymorphism on Intrinsic Disorder Propensity, Serological Cross-Reactivity and Cross-Protectivity of Isoforms

et al. 2016

View full text Add to dashboard Cite

Yersinia pestis Caf1 is a multifunctional protein responsible for antiphagocytic activity and is a key protective antigen. It is generally conserved between globally distributed Y. pestis strains, but Y. pestis subsp. microtus biovar caucasica strains circulating within populations of common voles in Georgia and Armenia were reported to carry a single substitution of alanine to serine. We investigated polymorphism of the Caf1 sequences among other Y. pestis subsp. microtus strains, which have a limited virulence in guinea pigs and in humans. Sequencing of caf1 genes from 119 Y. pestis strains belonging to different biovars within subsp. microtus showed that the Caf1 proteins exist in three isoforms, the global type Caf1NT1 (Ala48 Phe117), type Caf1NT2 (Ser48 Phe117) found in Transcaucasian-highland and Pre-Araks natural plague foci #4–7, and a novel Caf1NT3 type (Ala48 Val117) endemic in Dagestan-highland natural plague focus #39. Both minor types are the progenies of the global isoform. In this report, Caf1 polymorphism was analyzed by comparing predicted intrinsic disorder propensities and potential protein-protein interactivities of the three Caf1 isoforms. The analysis revealed that these properties of Caf1 protein are minimally affected by its polymorphism. All protein isoforms could be equally detected by an immunochromatography test for plague at the lowest protein concentration tested (1.0 ng/mL), which is the detection limit. When compared to the classic Caf1NT1 isoform, the endemic Caf1NT2 or Caf1NT3 had lower immunoreactivity in ELISA and lower indices of self- and cross-protection. Despite a visible reduction in cross-protection between all Caf1 isoforms, our data suggest that polymorphism in the caf1 gene may not allow the carriers of Caf1NT2 or Caf1NT3 variants escaping from the Caf1NT1-mediated immunity to plague in the case of a low-dose flea-borne infection.

show abstract

“…This immune response can protect different species of animals against bacterial pathogens, including bacteria with partially altered antigenic specificity, in case of both subcutaneous and aerosol administrations [ 3 , 7 - 11 ]. However, a commercial live plague vaccine created on the basis of the Yersinia pestis EV strain can cause local and systemic adverse reactions of varying severity in 5–29% of subjects with a normal immune status, regardless of route of administration [ 1 , 2 , 12 , 13 ]. Therefore, studies aimed at creating live plague vaccines based on precisely attenuated strains of Y. pestis with superior immunogenicity and reduced reactogenicity compared to those of the commercial EV vaccine strain remain relevant [ 2 , 8 , 14 - 19 ].…”

Section: Introductionmentioning

confidence: 99%

Selective Protective Potency of Yersinia pestis ΔnlpD Mutants

et al. 2015

Self Cite

View full text Add to dashboard Cite

It has recently been shown that the NlpD lipoprotein is essential to Yersinia pestis virulence and that subcutaneous administration of the nlpD mutant could protect mice against bubonic and pneumonic plague better than the EV vaccine strain [PLoS One 2009. V. 4. № 9. e7023]. In this study, similar ΔnlpD mutants were generated on the basis of other Y. pestis parent strains, including strains from the subspecies microtus, which is avirulent to guinea pigs and humans. Comparative testing confirmed that immunization of mice with ΔnlpD mutants induces immunity 105 times more potent than the one induced by the administration of the EV vaccine strain. At the same time, NlpD- bacteria failed to protect guinea pigs in the case of a subcutaneous challenge with Y. pestis, inducing a 106 times less potent protection compared with that conferred by immunization with the EV vaccine strain. The possible causes of the observed phenomena are discussed.

show abstract

Molecular bases of vaccine-prevention of plague

Cited by 17 publications

References 116 publications

Plague Vaccines: Status and Future

Plague Vaccines: Status and Future

Yersinia pestis Caf1 Protein: Effect of Sequence Polymorphism on Intrinsic Disorder Propensity, Serological Cross-Reactivity and Cross-Protectivity of Isoforms

Selective Protective Potency of Yersinia pestis ΔnlpD Mutants

Contact Info

Product

Resources

About